Pfizer–Trump $70B Deal: Red Flag Checklist for Corporate Betrayal or Public Benefit. Trump’s new $70 billion Pfizer deal raises big questions. Who really wins—patients or Big Pharma? Use this red flag checklist to spot hidden risks in pharma–government agreements.
From the Pen or keyboard of John Rappoport: The new Pfizer Trump deal just pledged—how horrible is it? First of all, the devil is in the details, and a lot of details aren’t yet available. Putting that aside, we DO SEE Trump going back to his old criminal friend, Pfizer CEO Albert Bourla, to make a deal. “Albert, great guy, great businessman.” There they are, just as they were at launch of the murderous Warp Speed. And Kennedy is in “stand-by mode.” Watching the two titans do their $$$ tap dance. Pfizer is promising to cut prices for some of its drugs, for Medicaid. Also, it will spend $70 billion to build research labs and manufacturing plants in the US, not in foreign countries. Trump, in return, will exempt Pfizer from tariffs applied to materials Pfizer has shipped to the US from foreign countries. Depending on how much those tariffs amount to over the next several years, Pfizer will essentially be “repaid” some or possibly all of its $70 billion investment. Right now, it looks lik...